Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis

Slide: 6 of 37

Rationale for Use of Recombinant Human Growth Hormone (rhGH) in Patients With CF

The rationale for the use of rhGH as an adjuvant therapy for patients with CF is based on the observation that despite an aggressive focus on treatment of nutritional needs as part of standard care, as many as one-third of patients with CF in the United States fall below the 10th percentile in height and weight. Patients with CF experience increased energy expenditure due to the high metabolic demands of their chronic illness. Better clinical outcomes for patients with CF have been associated with measures that improve growth. This finding has led investigators to suggest that treatment with the anabolic hormone rhGH may lead to better intermediate and long-term health outcomes and improved quality of life for patients with CF.